179 related articles for article (PubMed ID: 35761499)
1. Current Insights into the Role of BRAF Inhibitors in Treatment of Melanoma.
Singh AK; Kumar A; Thareja S; Kumar P
Anticancer Agents Med Chem; 2023; 23(3):278-297. PubMed ID: 35761499
[TBL] [Abstract][Full Text] [Related]
2. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
3. Mitogen-activated protein kinase (MEK) inhibitors to treat melanoma alone or in combination with other kinase inhibitors.
Faghfuri E; Nikfar S; Niaz K; Faramarzi MA; Abdollahi M
Expert Opin Drug Metab Toxicol; 2018 Mar; 14(3):317-330. PubMed ID: 29363351
[TBL] [Abstract][Full Text] [Related]
4. Molecular Targeting of the BRAF Proto-Oncogene/Mitogen-Activated Protein Kinase (MAPK) Pathway across Cancers.
Shan KS; Rehman TU; Ivanov S; Domingo G; Raez LE
Int J Mol Sci; 2024 Jan; 25(1):. PubMed ID: 38203795
[TBL] [Abstract][Full Text] [Related]
5. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
[TBL] [Abstract][Full Text] [Related]
6. MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition.
Wagle N; Van Allen EM; Treacy DJ; Frederick DT; Cooper ZA; Taylor-Weiner A; Rosenberg M; Goetz EM; Sullivan RJ; Farlow DN; Friedrich DC; Anderka K; Perrin D; Johannessen CM; McKenna A; Cibulskis K; Kryukov G; Hodis E; Lawrence DP; Fisher S; Getz G; Gabriel SB; Carter SL; Flaherty KT; Wargo JA; Garraway LA
Cancer Discov; 2014 Jan; 4(1):61-8. PubMed ID: 24265154
[TBL] [Abstract][Full Text] [Related]
7. Genetic Heterogeneity of BRAF Fusion Kinases in Melanoma Affects Drug Responses.
Botton T; Talevich E; Mishra VK; Zhang T; Shain AH; Berquet C; Gagnon A; Judson RL; Ballotti R; Ribas A; Herlyn M; Rocchi S; Brown KM; Hayward NK; Yeh I; Bastian BC
Cell Rep; 2019 Oct; 29(3):573-588.e7. PubMed ID: 31618628
[TBL] [Abstract][Full Text] [Related]
8. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
Ming Z; Lim SY; Kefford RF; Rizos H
Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
[TBL] [Abstract][Full Text] [Related]
9. MEK and RAF inhibitors for BRAF-mutated cancers.
Belden S; Flaherty KT
Expert Rev Mol Med; 2012 Oct; 14():e17. PubMed ID: 23058743
[TBL] [Abstract][Full Text] [Related]
10. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM
Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307
[TBL] [Abstract][Full Text] [Related]
11. Targeted Therapy for Melanoma.
Wong DJ; Ribas A
Cancer Treat Res; 2016; 167():251-62. PubMed ID: 26601866
[TBL] [Abstract][Full Text] [Related]
12. Clinical Development of BRAF plus MEK Inhibitor Combinations.
Subbiah V; Baik C; Kirkwood JM
Trends Cancer; 2020 Sep; 6(9):797-810. PubMed ID: 32540454
[TBL] [Abstract][Full Text] [Related]
13. Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway.
Grimaldi AM; Simeone E; Festino L; Vanella V; Palla M; Ascierto PA
Discov Med; 2015 Jun; 19(107):455-61. PubMed ID: 26175403
[TBL] [Abstract][Full Text] [Related]
14. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
Nakamura A; Arita T; Tsuchiya S; Donelan J; Chouitar J; Carideo E; Galvin K; Okaniwa M; Ishikawa T; Yoshida S
Cancer Res; 2013 Dec; 73(23):7043-55. PubMed ID: 24121489
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic targets in melanoma: map kinase pathway.
Haluska FG; Ibrahim N
Curr Oncol Rep; 2006 Sep; 8(5):400-5. PubMed ID: 16901402
[TBL] [Abstract][Full Text] [Related]
16. Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies.
Jang S; Atkins MB
Clin Pharmacol Ther; 2014 Jan; 95(1):24-31. PubMed ID: 24080641
[TBL] [Abstract][Full Text] [Related]
17. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.
Rose AAN
Drugs Today (Barc); 2019 Apr; 55(4):247-264. PubMed ID: 31050693
[TBL] [Abstract][Full Text] [Related]
18. Network indirect comparison of 3 BRAF + MEK inhibitors for the treatment of advanced BRAF mutated melanoma.
Consoli F; Bersanelli M; Perego G; Grisanti S; Merelli B; Berruti A; Petrelli F
Clin Transl Oncol; 2020 Jun; 22(6):900-907. PubMed ID: 31555967
[TBL] [Abstract][Full Text] [Related]
19. Targeting RAS/RAF/MEK/ERK signaling in metastatic melanoma.
Wang AX; Qi XY
IUBMB Life; 2013 Sep; 65(9):748-58. PubMed ID: 23893853
[TBL] [Abstract][Full Text] [Related]
20. BRAF inhibitors promote intermediate BRAF(V600E) conformations and binary interactions with activated RAS.
Röck R; Mayrhofer JE; Torres-Quesada O; Enzler F; Raffeiner A; Raffeiner P; Feichtner A; Huber RG; Koide S; Taylor SS; Troppmair J; Stefan E
Sci Adv; 2019 Aug; 5(8):eaav8463. PubMed ID: 31453322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]